Thermo Fisher Scientific Introduces Invitrogen™ Vivofectamine™ Delivery Solutions To Help Advance Life Science Research and Genetic Medicines

Thermo Fisher Scientific has introduced the Invitrogen Vivofectamine™ Delivery Solutions to provide high-performance lipid nanoparticles (LNP) technology for non-viral delivery of nucleic acids, helping advance life science research and genetic medicine development. This innovative LNP portfolio, curated from over 6,000 rationally designed, chemically diverse ionizable lipids, offers in vivo delivery solutions in various application areas with the desired efficiency, specificity and safety profiles.

 

One of the key challenges in genetic medicine is how to deliver nucleic acids, such as RNA or DNA, to a target organ or cell type while maintaining their integrity and without causing major side effects. The increasing interest in LNP delivery technology in recent years has been driven by both the global validation of LNP-delivered COVID mRNA vaccines in humans, and growing safety concerns with viral delivery methods. The adoption of LNP technology as a non-viral delivery alternative is accelerating for prophylactic and cancer vaccines, gene replacement, gene editing therapies, as well as in vivo and ex vivo immune cell therapies, and stem cell therapy.

Invitrogen’s Vivofectamine Delivery Solutions offer two tailored portfolios: the basic research portfolio with catalog LNP reagents for academic researchers, and the drug development portfolio with custom LNP reagents and services for drug developers. Together, both portfolios enable scientists globally to help reduce the time and cost of their advanced innovations.

 

“Drawing on decades of experience in lipid-based delivery of nucleic acids in vitro with the widely recognized brand, Lipofectamine™, Thermo Fisher’s Vivofectamine Delivery Solutions utilizing advanced LNP technologies are specifically designed to help facilitate the safe and effective in vivo delivery of nucleic acids,” said Tiffani Manolis, vice president, cell biology, Thermo Fisher Scientific. “This new era of non-viral delivery technologies helps inspire innovation in life science research and can pave the way for groundbreaking genetic medicines.”

Invitrogen Vivofectamine Delivery Solutions are intended for research use only. They are suitable for institutions conducting basic research, as well as biotechnology and biopharmaceutical companies involved in drug development for nucleic acid modalities.

Features/Benefits:

• Versatility. The Vivofectamine LNPs were developed through iterative cycles of rational ionizable lipid design, synthesis, formulation optimization, characterization, and in vitro and in vivo biological screening. They are available in a variety of reagent formats and come with value-added services. Additionally, adaptable licensing terms are offered to tailor to different drug developers’ needs.
• Safety. Various Vivofectamine LNPs were tested by collaborators through repeated, escalated dosing and maximum tolerated dose regimes in non-human primates and rat studies and benchmarked against leading LNPs used in relevant clinical stage or FDA approved drugs.
• Helping accelerate innovation with proven in vivo delivery solutions. Vivofectamine LNPs have been extensively optimized and tested in multiple animal models for intramuscular delivery in prophylactic and cancer vaccines, as well as systemic delivery to the liver. Our collaborators have also shared preliminary feasibility data on extra-hepatic systemic delivery to immune cells, muscles, and local delivery, to areas such as tumors, eyes, adipose tissue, and the central nervous system (CNS).